These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38734314)
21. Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and fungizone against intracellular Candida albicans in murine peritoneal macrophages. van Etten EW; van Vianen W; Hak J; Bakker-Woudenberg IA Antimicrob Agents Chemother; 1998 Sep; 42(9):2437-9. PubMed ID: 9736579 [TBL] [Abstract][Full Text] [Related]
22. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021 [TBL] [Abstract][Full Text] [Related]
23. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Italia JL; Yahya MM; Singh D; Ravi Kumar MN Pharm Res; 2009 Jun; 26(6):1324-31. PubMed ID: 19214716 [TBL] [Abstract][Full Text] [Related]
24. PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome. Van de Ven H; Paulussen C; Feijens PB; Matheeussen A; Rombaut P; Kayaert P; Van den Mooter G; Weyenberg W; Cos P; Maes L; Ludwig A J Control Release; 2012 Aug; 161(3):795-803. PubMed ID: 22641062 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections. Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151 [TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. Gangadhar KN; Adhikari K; Srichana T Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597 [TBL] [Abstract][Full Text] [Related]
27. Synthesis and evaluation of styrene-maleic acid copolymer conjugated amphotericin B. Banshoya K; Kaneo Y; Tanaka T; Yamamoto S; Maeda H Int J Pharm; 2019 Dec; 572():118719. PubMed ID: 31654700 [TBL] [Abstract][Full Text] [Related]
28. Targeted delivery of amphotericin B-loaded PLGA micelles displaying lipopeptides to drug-resistant Candida-infected skin. Kim YM; Guk T; Jang MK; Park SC; Lee JR Int J Biol Macromol; 2024 Nov; 279(Pt 3):135402. PubMed ID: 39245114 [TBL] [Abstract][Full Text] [Related]
29. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Zia Q; Khan AA; Swaleha Z; Owais M Int J Nanomedicine; 2015; 10():1769-90. PubMed ID: 25784804 [TBL] [Abstract][Full Text] [Related]
30. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. Italia JL; Sharp A; Carter KC; Warn P; Kumar MN PLoS One; 2011; 6(10):e25744. PubMed ID: 21998690 [TBL] [Abstract][Full Text] [Related]
31. Linolenic acid-modified methoxy poly (ethylene glycol)-oligochitosan conjugate micelles for encapsulation of amphotericin B. Song Z; Wen Y; Deng P; Teng F; Zhou F; Xu H; Feng S; Zhu L; Feng R Carbohydr Polym; 2019 Feb; 205():571-580. PubMed ID: 30446143 [TBL] [Abstract][Full Text] [Related]
32. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. van Etten EW; Chander HR; Snijders SV; Bakker-Woudenberg IA J Antimicrob Chemother; 1995 Dec; 36(6):961-74. PubMed ID: 8821595 [TBL] [Abstract][Full Text] [Related]
33. Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations. Dinh T; Zia Q; Zubair S; Stapleton P; Singh R; Owais M; Somavarapu S Nanomedicine; 2017 Jul; 13(5):1773-1783. PubMed ID: 28216150 [TBL] [Abstract][Full Text] [Related]
34. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles. Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532 [TBL] [Abstract][Full Text] [Related]
35. Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B. Yu BG; Okano T; Kataoka K; Kwon G J Control Release; 1998 Apr; 53(1-3):131-6. PubMed ID: 9741920 [TBL] [Abstract][Full Text] [Related]
37. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697 [TBL] [Abstract][Full Text] [Related]
38. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature. Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660 [TBL] [Abstract][Full Text] [Related]
39. Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. Vakil R; Knilans K; Andes D; Kwon GS Pharm Res; 2008 Sep; 25(9):2056-64. PubMed ID: 18415047 [TBL] [Abstract][Full Text] [Related]
40. Characterization of a Polyethylene Glycol-Amphotericin B Conjugate Loaded with Free AMB for Improved Antifungal Efficacy. Tan TR; Hoi KM; Zhang P; Ng SK PLoS One; 2016; 11(3):e0152112. PubMed ID: 27008086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]